Browse the evidence

GLP-1 receptor agonists have shown promising results in reducing liver enzymes and improving MASLD.

Practitioners may consider GLP-1 RAs as a therapeutic option for MASLD.

The long-acting GIPR agonist LY3537021 induced a mean body weight loss of 3.14 kg in participants with T2D compared to 0.36 kg in the placebo group at day 57 (p < 0.05).

LY3537021 may be an effective treatment option for weight loss in patients with T2D.

LY3537021 was well tolerated with infrequent gastrointestinal adverse events.

LY3537021 may be a safe option for patients with T2D.

Retatrutide (LY3437943) is a novel triple agonist that targets GLP-1, GIP, and glucagon receptors, representing a transformative advance in obesity pharmacotherapy.

Retatrutide may be considered as a new treatment option for obesity.

Glucagon-like peptide-1 receptor agonists may encourage a more holistic approach to treatment of CKM syndrome.

Clinicians should consider using GLP-1 receptor agonists for integrated treatment strategies.

The efficacy of GLP-1 receptor agonists was consistent across other important subpopulations.

GLP-1 receptor agonists can be considered effective for weight loss across diverse patient groups.

Insulin therapy often leads to fat mass accumulation and increases the risk of sarcopenic obesity.

Practitioners should be cautious of insulin therapy's potential to increase fat mass and risk of sarcopenic obesity.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.

Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.

The proposed nanocomplex is a promising system for long-acting injectable delivery of semaglutide, potentially enhancing patient compliance.

This delivery system may improve treatment adherence in patients requiring semaglutide.

GLP-1 RA initiation was associated with a reduced incidence rate of alcohol use disorders (AUD) post RYGB (1.1% vs. 1.8%) with a hazard ratio of 0.77.

Practitioners may consider GLP-1 RAs as a strategy to reduce AUD in patients post RYGB.

GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).

GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.

The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.

Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.

HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.

Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.

Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.

Stay informed about new incretin agents for T2D prevention and treatment.

Abdominoplasty following GLP-1 RA-induced massive weight loss shows a trend toward a lower overall complication rate (20% vs 40%) compared to postbariatric surgery.

Practitioners may consider GLP-1 RA therapy as a safer option for patients seeking abdominoplasty after significant weight loss.

Leptin levels significantly decline following semaglutide treatment, particularly in the obesity group (-5.10 ng/mL).

Semaglutide may help lower leptin levels, which could be beneficial for weight management in diabetic patients.

Adiponectin levels increase significantly post-semaglutide add-on therapy, with the greatest increase in the obesity group (+3.70 μg/mL).

Increased adiponectin levels with semaglutide may enhance metabolic health in diabetic patients.

Long-term mortality was significantly lower in the GLP-1 group (odds ratio 0.58, 95% CI 0.36-0.94).

GLP-1 receptor agonists may improve long-term survival in patients undergoing endovascular treatment for aneurysms.

Obesity is associated with menstrual irregularities, poorer reproductive and obstetric outcomes, and an increased risk of endometrial cancer.

Clinicians should be aware of the reproductive health risks associated with obesity in women.

Both doses of tirzepatide (10 mg and 15 mg) showed significantly greater reductions in predicted diabetes risk compared to placebo.

Practitioners may consider the effectiveness of tirzepatide over placebo in reducing diabetes risk.

Effective weight loss, even when accompanied by gastrointestinal side effects, was associated with a greater willingness to continue Ozempic treatment.

Practitioners should emphasize the importance of weight loss effectiveness in encouraging patients to continue treatment despite side effects.

Semaglutide offers robust cardiovascular protection.

Clinicians can consider semaglutide for patients needing cardiovascular protection in obesity management.

GLP-1RAs appear to be safe and effective in patients with inflammatory bowel disease (IBD).

Healthcare providers can consider GLP-1RAs as a treatment option for IBD patients.

GLP-1RA users demonstrated significantly reduced pseudarthrosis rates at all time points: 6 months (8% vs. 12%; OR=0.702), 12 months (OR=0.730), and 24 months postoperatively (OR=0.788).

GLP-1RAs may be beneficial in reducing complications like pseudarthrosis in ACDF patients.